
Thx to @JAMANetworkOpen for publishing our cost-effectiveness study of periop EV-pembro for cisplatin-ineligible MIBC @MaxKates @SBoorjian @tbivala1 @m_e_nielsen @siadaneshmand @SHPatelMD1 @nirmishsingla @JCensits @akfsurgeon @Sood11 @HitenDPatel @RuchikaTalwarMD @brady_urology
For cisplatin-ineligible muscle-invasive #BladderCancer, perioperative #EnfortumabVedotin plus pembrolizumab with radical cystectomy was associated with improved survival and was cost-effective vs radical cystectomy alone over 10 years. ja.ma/4seltqJ

































